Effect of tumor-specific KRAS mutational status on impact of anti-EGFR therapy in non-small cell lung cancer (NSCLC).
作者： M. C. Garassino , M. Marabese , M. Broggini , C. Lauricella , I. Floriani
DOI: 10.1200/JCO.2010.28.15_SUPPL.7564
关键词: Oncology 、 Medicine 、 Tumor specific 、 Mutational status 、 MAPK/ERK pathway 、 Internal medicine 、 KRAS 、 non-small cell lung cancer (NSCLC) 、 Cancer
摘要: 7564 Background: The RAS/RAF/MEK/ERK pathway is a therapeutic target in both colorectal (CRC) and NSCLC cancer, but while mutated KRAS negative prognostic marker predictor for a...
sci-hub.st 参考文章(0)